Literature DB >> 23269484

Statins reduce amyloid β-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons.

Ai Hosaka1, Wataru Araki, Akiko Oda, Yasushi Tomidokoro, Akira Tamaoka.   

Abstract

Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, have been reported to attenuate amyloid-β peptide (Aβ) production in various cellular models. However, the mechanisms by which statins affect neuronal Aβ production have not yet been clarified. Here, we investigated this issue in rat primary cortical neurons using two statins, pitavastatin (PV) and atorvastatin (AV). Treatment of neurons with 0.2-2.5 μM PV or AV for 4 days induced a concentration- and time-dependent reduction in the secretion of both Aβ40 and Aβ42. Moreover, Western blot analyses of cell lysates showed that treatment with PV or AV significantly reduced expression levels of the mature form of amyloid precursor protein (APP) and Thr668-phosphorylated APP (P-APP), but not immature form of APP; the decreases in P-APP levels were more notable than those of mature APP levels. The statin treatment did not alter expression of BACE1 (β-site APP-cleaving enzyme 1) or γ-secretase complex proteins (presenilin 1, nicastrin, APH-1, and PEN-2). In neurons overexpressing APP via recombinant adenoviruses, PV or AV similarly reduced Aβ secretion and the levels of mature APP and P-APP. Statins also markedly reduced cellular cholesterol content in neurons in a concentration-dependent manner. Co-treatment with mevalonate reversed the statin-induced decreases in Aβ secretion and mature APP and P-APP levels, whereas co-treatment with cholesterol did not, despite recovery of cellular cholesterol levels. Finally, cell-surface biotinylation experiments revealed that both statins significantly reduced the levels of cell-surface P-APP without changing those of cell surface mature APP. These results suggest that statins reduce Aβ production by selectively modulating APP maturation and phosphorylation through a mechanism independent of cholesterol reduction in cultured neurons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269484     DOI: 10.1007/s11064-012-0956-1

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  54 in total

1.  Extracellular release of BACE1 holoproteins from human neuronal cells.

Authors:  Kiyoko S Murayama; Fuyuki Kametani; Wataru Araki
Journal:  Biochem Biophys Res Commun       Date:  2005-10-13       Impact factor: 3.575

2.  Processing of the amyloid protein precursor to potentially amyloidogenic derivatives.

Authors:  T E Golde; S Estus; L H Younkin; D J Selkoe; S G Younkin
Journal:  Science       Date:  1992-02-07       Impact factor: 47.728

3.  Oxidative stress up-regulates presenilin 1 in lipid rafts in neuronal cells.

Authors:  Akiko Oda; Akira Tamaoka; Wataru Araki
Journal:  J Neurosci Res       Date:  2010-04       Impact factor: 4.164

Review 4.  Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration.

Authors:  Chen Pac-Soo; Dafydd G Lloyd; Marcela P Vizcaychipi; Daqing Ma
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 5.  Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations.

Authors:  Nina E Shepardson; Ganesh M Shankar; Dennis J Selkoe
Journal:  Arch Neurol       Date:  2011-11

6.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

7.  Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis.

Authors:  Elzbieta Kojro; Petra Füger; Claudia Prinzen; Anna Maria Kanarek; Dorothea Rat; Kristina Endres; Falk Fahrenholz; Rolf Postina
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury.

Authors:  Bo Li; Asim Mahmood; Dunyue Lu; Hongtao Wu; Ye Xiong; Changsheng Qu; Michael Chopp
Journal:  Neurosurgery       Date:  2009-07       Impact factor: 4.654

10.  JNK3 perpetuates metabolic stress induced by Aβ peptides.

Authors:  Sung Ok Yoon; Dong Ju Park; Jae Cheon Ryu; Hatice Gulcin Ozer; Chhavy Tep; Yong Jae Shin; Tae Hee Lim; Lucia Pastorino; Ajaya J Kunwar; James C Walton; Alan H Nagahara; Kun Ping Lu; Randy J Nelson; Mark H Tuszynski; Kun Huang
Journal:  Neuron       Date:  2012-09-06       Impact factor: 17.173

View more
  11 in total

1.  Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage.

Authors:  Hai-juan Sui; Ling-ling Zhang; Zhou Liu; Ying Jin
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

2.  Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway.

Authors:  Ling-Ling Zhang; Hai-Juan Sui; Bing Liang; Han-Ming Wang; Wen-Hui Qu; Sheng-Xue Yu; Ying Jin
Journal:  Acta Pharmacol Sin       Date:  2014-05-05       Impact factor: 6.150

3.  Targeting the TLR4/NF-κΒ Axis and NLRP1/3 Inflammasomes by Rosuvastatin: A Role in Impeding Ovariectomy-Induced Cognitive Decline Neuropathology in Rats.

Authors:  Muhammed A Saad; Muhammad Y Al-Shorbagy; Hany H Arab
Journal:  Mol Neurobiol       Date:  2022-05-17       Impact factor: 5.590

4.  Statin therapy exacerbates alcohol-induced constriction of cerebral arteries via modulation of ethanol-induced BK channel inhibition in vascular smooth muscle.

Authors:  Maria N Simakova; Shivantika Bisen; Alex M Dopico; Anna N Bukiya
Journal:  Biochem Pharmacol       Date:  2017-09-01       Impact factor: 5.858

5.  Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of AβPP into Amyloidogenic Processing Pathway.

Authors:  Carolyn L Fisher; Ross J Resnick; Soumya De; Lucila A Acevedo; Kun Ping Lu; Frank C Schroeder; Linda K Nicholson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Kynurenines and other novel therapeutic strategies in the treatment of dementia.

Authors:  Zsófia Majláth; János Tajti; László Vécsei
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

Review 7.  Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.

Authors:  Angela Jeong; Kiall Francis Suazo; W Gibson Wood; Mark D Distefano; Ling Li
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-06       Impact factor: 8.250

Review 8.  Molecular mechanisms underlying the effects of statins in the central nervous system.

Authors:  Amelia J McFarland; Shailendra Anoopkumar-Dukie; Devinder S Arora; Gary D Grant; Catherine M McDermott; Anthony V Perkins; Andrew K Davey
Journal:  Int J Mol Sci       Date:  2014-11-10       Impact factor: 5.923

9.  Rosuvastatin Reduces Neuroinflammation in the Hemorrhagic Transformation After rt-PA Treatment in a Mouse Model of Experimental Stroke.

Authors:  Dan Lu; Yanfang Liu; Hongcheng Mai; Jiankun Zang; Lingling Shen; Yusheng Zhang; Anding Xu
Journal:  Front Cell Neurosci       Date:  2018-08-02       Impact factor: 5.505

Review 10.  The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease.

Authors:  Marcus O W Grimm; Valerie C Zimmer; Johannes Lehmann; Heike S Grimm; Tobias Hartmann
Journal:  Biomed Res Int       Date:  2014-02-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.